Liquid chromatography–tandem mass spectrometric assay for the PARP inhibitor rucaparib in plasma
- 23 October 2013
- journal article
- research article
- Published by Elsevier BV in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 88, 626-629
- https://doi.org/10.1016/j.jpba.2013.10.016
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiationCancer Chemotherapy and Pharmacology, 2013
- Liquid chromatography–tandem mass spectrometric assay for the PARP-1 inhibitor olaparib in combination with the nitrogen mustard melphalan in human plasmaJournal of Chromatography B, 2011
- Poly(ADP-Ribose) Polymerase InhibitorsThe Cancer Journal, 2010
- Liquid chromatography-tandem mass spectrometric assay for the light sensitive tyrosine kinase inhibitor axitinib in human plasmaJournal of Chromatography B, 2009
- Phase I Study of the Poly (ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid TumorsClinical Cancer Research, 2008
- A study of the analytical behaviour of selected new molecular entities using electrospray ionisation ion trap mass spectrometry, liquid chromatography, gas chromatography and polarography and their determination in serum at therapeutic concentrationsAnalytica Chimica Acta, 2008
- Specific method for determination of gefitinib in human plasma, mouse plasma and tissues using high performance liquid chromatography coupled to tandem mass spectrometryJournal of Chromatography B, 2005